These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26033434)

  • 1. Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.
    Singh P; Tomar RS; Rath SK
    Mol Biol Rep; 2015 Nov; 42(11):1515-31. PubMed ID: 26033434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plant flavone Chrysin as an emerging histone deacetylase inhibitor for prosperous epigenetic-based anticancer therapy.
    Ganai SA; Sheikh FA; Baba ZA
    Phytother Res; 2021 Feb; 35(2):823-834. PubMed ID: 32930436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
    Markozashvili D; Ribrag V; Vassetzky YS
    Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
    Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
    J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
    Miller CP; Singh MM; Rivera-Del Valle N; Manton CA; Chandra J
    J Biomed Biotechnol; 2011; 2011():514261. PubMed ID: 21765634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.
    Zhang L; Han Y; Jiang Q; Wang C; Chen X; Li X; Xu F; Jiang Y; Wang Q; Xu W
    Med Res Rev; 2015 Jan; 35(1):63-84. PubMed ID: 24782318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic agents in combined anticancer therapy.
    Kejík Z; Jakubek M; Kaplánek R; Králová J; Mikula I; Martásek P; Král V
    Future Med Chem; 2018 May; 10(9):1113-1130. PubMed ID: 29676175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDACiDB: a database for histone deacetylase inhibitors.
    Murugan K; Sangeetha S; Ranjitha S; Vimala A; Al-Sohaibani S; Rameshkumar G
    Drug Des Devel Ther; 2015; 9():2257-64. PubMed ID: 25945037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.
    Banik D; Moufarrij S; Villagra A
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
    Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
    Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of histone deacetylase inhibitors for bladder cancer treatment.
    Tanji N; Ozawa A; Kikugawa T; Miura N; Sasaki T; Azuma K; Yokoyama M
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):959-65. PubMed ID: 21707293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer.
    Li X; Xu W
    Drug Discov Ther; 2014 Oct; 8(5):225-8. PubMed ID: 25382558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.